V930 First in Man (FIM) Study (V930-002)(COMPLETED)

NCT00250419 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancers Expressing HER-2 and/or CEA

Interventions

BIOLOGICAL: V930

Sponsor

Merck Sharp & Dohme LLC